Efprezimod alfa + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Disease 2019 (COVID-19)
Conditions
Coronavirus Disease 2019 (COVID-19)
Trial Timeline
Apr 24, 2020 → Oct 20, 2020
NCT ID
NCT04317040About Efprezimod alfa + Placebo
Efprezimod alfa + Placebo is a phase 3 stage product being developed by Merck for Coronavirus Disease 2019 (COVID-19). The current trial status is completed. This product is registered under clinical trial identifier NCT04317040. Target conditions include Coronavirus Disease 2019 (COVID-19).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04317040 | Phase 3 | Completed |
Competing Products
20 competing products in Coronavirus Disease 2019 (COVID-19)